US › Healthcare

PTC Therapeutics Inc (PTCT)

US · Healthcare · Biotechnology

$69.10+1.45%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$272.6M
Revenue YoY
-76.8%
Net profit
$-2.8M
Profit YoY
-100.3%
EPS
$-0.03
EPS estimate
$-0.44
Net margin
-1.0%

EPS came in at -0.03 against a street estimate of -0.44 — a beat of 93.2%.

Key statistics

Market cap
$6.18B
Forward P/E
39.5
P/B
1,743.27
Book value
$-2.18
EPS (TTM)
$-2.51
52-week high
$90.87
52-week low
$43.17
50-day MA
$77.08
200-day MA
$73.06
Beta
0.53

Analyst view

Analysts rate PTC Therapeutics Inc a buy (9 buy, 4 hold, 1 sell out of 14) with an average price target of $96.07.

Shareholding

Insiders
7.38%
Institutions
118.25%

Largest institutional holders

FundStake
BlackRock Inc15.62%
Vanguard Group Inc10.62%
RTW INVESTMENTS, LLC9.34%
HHG PLC8.68%
Vanguard Portfolio Management, LLC5.79%
State Street Corp5.24%
Wellington Management Company LLP4.76%
Vanguard Capital Management, LLC4.43%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for PTC Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.